Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study / Detomas, M; Altieri, B; Deutschbein, T; Fassnacht, M; Dischinger, U. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - (2022). [10.3389/fendo.2022.903545]

Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study

Altieri B;
2022-01-01

2022
Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study / Detomas, M; Altieri, B; Deutschbein, T; Fassnacht, M; Dischinger, U. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - (2022). [10.3389/fendo.2022.903545]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/3019306
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact